Akero Therapeutics
About
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
- 11 - 50
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $100M
- Industries
- Biotechnology,Life Science,Therapeutics
- Founded date
- Jan 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure, and death. The company is developing pioneering medicines designed to restore metabolic balance and halt NASH progression. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH. The AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 16, 2022 | Post-IPO Debt | $100M | 1 |
Hercules Capital
|
— | Detail |
| Dec 12, 2018 | Series B | $70M | 1 | — | — | Detail |
| Jun 25, 2018 | Series A | $65M | 1 |
Versant Ventures
|
— | Detail |
Investments
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
|
Versant Ventures
|
— | Series B |
